Robert E. Conway, Director at Nivalis Therapeutics, Inc. (NVLS), bought 20,000 shares at $2.30 ($46K) on 2017-05-05, disclosed to the SEC on 2017-05-09.
Open-market purchase of $46k NVLS by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| ALPN | BUY | 2021-09-23 | $98K | — | Filing → |
| ABIO | BUY | 2021-05-13 | $32K | — | Filing → |
| ABIO | BUY | 2021-05-06 | $32K | — | Filing → |